Mindera Health

Mindera Health develops precision medicine diagnostics for dermatological conditions, specifically psoriasis. The company's flagship product, Mind.Px™, is a non-invasive diagnostic patch that captures thousands of RNA transcripts from a penny-sized skin sample in approximately five minutes. The device employs Dermal Intelligence™ technology to enable scalable collection and analysis of individualized genetic information, providing actionable, data-driven treatment guidance for patients, providers, and payers. Mind.Px is designed to support biologic therapy selection for psoriasis patients, reducing trial-and-error treatment approaches. The company markets directly to healthcare providers and patients, offering physician resources, online test ordering, and patient education materials. Mindera Health has received regulatory approval from the New York State Department of Health as of April 2026, enabling national availability across all 50 states. The platform combines genomic RNA analysis with clinical dermatology to support precision treatment decisions. Target users include dermatologists, rheumatologists, and other providers managing psoriasis patients seeking to optimize biologic therapy outcomes.